Sunesis Pharmaceuticals, Inc. to Present at Rodman & Renshaw Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 8 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will present a company update at the Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo, Monaco on May 14, 2007 at 8:20 a.m. local time.

Interested parties may access the webcast of the presentation by visiting the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the “Calendar of Events” page in the Investors and Media section of the Sunesis website for two weeks until May 28, 2007.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.

Sunesis Pharmaceuticals, Inc.

CONTACT: investors, Eric Bjerkholt, SVP, Corp. Development & Finance ofSunesis Pharmaceuticals, Inc., +1-650-266-3717; or media, Karen L. Bergman,+1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partnersfor Sunesis Pharmaceuticals, Inc.

MORE ON THIS TOPIC